A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study of an Anti-IL-13 Monoclonal Antibody in Healthy Subjects and Mild Asthmatics

British Journal of Clinical Pharmacology, 05/25/2012

GSK679586 demonstrated dose–dependent pharmacological activity in the lungs of mild intermittent asthmatics. These findings, together with the favorable safety profile and advantageous PK characteristics of a monoclonal antibody (e.g. a long half–life supporting less frequent dosing), warrant further investigation of GSK679586 in a broader asthma patient population.

Print Article Summary Cat 2 CME Report